Dianze Chen

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)

Yongping Song, D. Liu, Jifeng Yu, 2022, Molecules.

Comparative study of the influence of two nursing modes on the perioperative period of 56 neonates with congenital esophageal atresia

W. Lu, Hai-hang Zhu, Li Zhang, 2016 .

Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients

T. Liang, Jie Wu, Z. Tu, 2022, Infection and drug resistance.

Abstract 545: Preclinical development of a bispecific antibody-trap selectively targeting CD47 and CD20 for the treatment of B cell lineage cancer

Liang Peng, Chunmei Yang, Wenzhi Tian, 2019, Clinical Research (Excluding Clinical Trials).

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal

Yongping Song, D. Liu, Jifeng Yu, 2022, Journal of Hematology & Oncology.

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling

D. Liu, Wenzhi Tian, Song Li, 2023, Frontiers in oncology.

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy

D. Liu, Jifeng Yu, Wenzhi Tian, 2023, Antibody therapeutics.

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38

D. Liu, Wenzhi Tian, Song Li, 2024, Frontiers in Immunology.